Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. is a contract research organization offering preclinical services globally. Its segments include Research Models
Charles River Laboratories International, Inc. is a contract research organization offering preclinical services globally. Its segments include Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The company recently divested certain discovery and CDMO businesses to focus on core regulated testing, serving pharmaceutical and biotechnology clients, including small/mid-sized biotechs and global biopharma.
Metric/field Biotechnology & Pharma - VC Deal Value (USD billions)
Cadence Quarterly
Why it matters Directly correlates with small-to-mid-cap biotech R&D spending, a primary driver of demand for CRO services.
Signal to watch Increasing value indicates higher R&D spending and outsourcing, bullish for CRL.
Confidence: high
Metric/field Total NIH Appropriations (USD billions)
Cadence Annually (with ongoing legislative updates)
Why it matters Influences academic and government research spending, impacting CRL's RMS segment.
Signal to watch Increasing or stable appropriations indicate stable or growing demand from academic/government clients.
Confidence: high
Metric/field FEDFUNDS (Effective Federal Funds Rate)
Cadence Daily/Monthly Average
Why it matters Higher interest rates can constrain biotech funding, impacting R&D budgets and CRO demand.
Signal to watch Declining or stable rates are favorable for biotech funding and CRO demand.
Confidence: medium
Metric/field CPIAUCSL (Consumer Price Index for All Urban Consumers: All Items in U.S. City Average)
Cadence Monthly
Why it matters Persistent inflation can increase operational costs for CRL, impacting margins.
Signal to watch Declining or stable inflation indicates reduced cost pressures.
Confidence: medium
Metric/field Global Pharmaceutical R&D Spending (USD billions)
Cadence Annually/Quarterly (from reports)
Why it matters Direct indicator of the overall R&D investment by CRL's primary client base, global biopharmaceutical companies.
Signal to watch Increasing spending indicates higher demand for CRO services.
Confidence: high
Metric/field Number of Biotech IPOs (Global)
Cadence Quarterly/Monthly
Why it matters IPO activity is a strong indicator of investor confidence and funding availability for new and growing biotech companies, which are key clients for CRL's early-stage services.
Signal to watch Increasing number of IPOs signals a healthier funding environment and potential for increased R&D outsourcing.
Confidence: high
Metric/field Number of New Studies Registered (filtered by "Study Start Date" - monthly)
Cadence Monthly
Why it matters Indicates the overall health and pipeline activity of the pharmaceutical and biotechnology industries, providing a forward-looking view on the volume of work for CROs.
Signal to watch Increasing number of new study registrations suggests growing demand for drug development services.
Confidence: high
Metric/field Search Interest Index for "drug discovery services"
Cadence Weekly
Why it matters Reflects general industry and public interest in drug discovery, which can be a proxy for underlying activity and awareness.
Signal to watch Rising search interest suggests increased focus and potential activity in the drug discovery space.
Confidence: medium
Metric/field r/biotech Subscriber Count
Cadence Daily/Weekly
Why it matters Provides a pulse on sentiment, discussion volume, and community growth within the biotech sector, which can indirectly signal industry health and funding sentiment.
Signal to watch Increasing subscriber count and engagement suggest growing interest and activity in the biotech community.
Confidence: low
Metric/field Total NIH Grant Funding Awarded (USD)
Cadence Quarterly
Why it matters Directly impacts funding for academic and government clients, which are important for CRL's RMS segment.
Signal to watch Increasing or stable grant funding indicates a healthy environment for academic and government research.
Confidence: high
Metric/field Biotechnology & Pharma - VC Deal Value (USD billions)
Cadence Monthly/Quarterly
Why it matters Granular and timely data on venture capital funding directly drives demand for early-stage CRO services.
Signal to watch Sustained increase in deal value indicates robust funding for biotech, leading to higher demand for CRL.
Confidence: high
Metric/field Total Job Postings for Contract Research Organizations (CROs)
Cadence Weekly/Monthly
Why it matters Provides an early signal on strategic investment areas, geographic expansion, and overall confidence in future growth across the CRO industry.
Signal to watch Increasing job postings suggest industry expansion and demand for CRO services.
Confidence: high
Metric/field Charles River Laboratories Employee Headcount (Global)
Cadence Monthly
Why it matters Changes in employee headcount can indicate capacity adjustments, operational efficiency, and growth expectations for CRL.
Signal to watch Increasing headcount suggests expansion and anticipation of higher demand.
Confidence: medium
Metric/field Global Clinical Trial Patient Enrollment (cumulative, by phase)
Cadence Monthly/Quarterly
Why it matters Direct measure of clinical trial activity and the volume of work for CROs involved in later-stage development.
Signal to watch Rising enrollment numbers indicate a healthy and active clinical pipeline, driving demand for CRO services.
Confidence: high
Metric/field Count of Biopharma R&D Pipeline Updates (e.g., new drug candidates, phase advancements)
Cadence Daily/Weekly
Why it matters Provides real-time insights into the pace of drug discovery and development across the biopharma industry, indicating potential future demand for CRO services.
Signal to watch Increasing frequency of pipeline updates suggests a more active and expanding drug development landscape.
Confidence: medium
Charles River Laboratories is positioned for growth, driven by a strengthening biopharmaceutical demand environment, particularly in Discovery and Safety Assess
Charles River Laboratories is positioned for growth, driven by a strengthening biopharmaceutical demand environment, particularly in Discovery and Safety Assessment (DSA), and robust biotech funding recovery. Strategic portfolio refinement, control over the non-human primate (NHP) supply chain, and deepening AI integration enhance its competitive advantage. While challenges persist from certain segment weaknesses and stable pricing, strong bookings and expected margin expansion in the second half of 2026 suggest a cautiously bullish outlook. (Updated: 2026-09-02)
Charles River Laboratories exceeded its Q2 2026 financial outlook, with a return to 0.1% organic revenue growth for the first time since Q3 2023. The DSA segment's net book-to-bill rose to nearly 1.2x, marking the third consecutive quarter above 1x and the highest in nearly four years, driven by strengthening demand from both small/mid-sized biotechs and global biopharma clients.
The company's strategic divestitures of certain European discovery, CDMO, and Cell Solutions businesses have streamlined its portfolio, focusing on core regulated testing solutions and contributing to a 420 basis point sequential operating margin improvement in Q2. Furthermore, the acquisition of NHP suppliers in Cambodia and Mauritius provides a reliable supply, creating a significant competitive advantage in safety assessment studies and is expected to drive substantial margin benefits in Q4 2026.
CRL is actively integrating advanced technologies, including AI, into its operations and client offerings. Collaborations like the one with Eli Lilly's TuneLab for AI/ML drug discovery and internal digital pathology solutions are enhancing efficiency and accelerating drug discovery. Organic investments in lab sciences and bioanalysis, with five global expansions underway, further support future growth and scientific capabilities.
The Research Models and Services (RMS) segment continues to face headwinds, with a 1.4% organic revenue decline in Q2 2026. This is primarily due to lower volumes for small models in North America and research model services, as spending from academic and government clients remains constrained by flat NIH budgets and slower grant processing.
Despite strengthening demand, pricing in the CRO market has not materially improved, remaining stable at levels seen over the last few years without significant increases or decreases in discounting. The competitive landscape, particularly in early-stage chemistry and biology services, has structurally shifted to lower-cost regions like China, posing ongoing challenges.
Operational pressures include higher-than-expected unallocated corporate costs in Q2 2026 and an increased non-GAAP tax rate outlook (23-24%) for the full year, partly due to proposed foreign tax legislation in Mauritius, which is expected to be a $0.20 headwind to EPS. The recovery in DSA, while positive, is still anticipated to be gradual.
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| DSA Net Book-to-Bill Ratio | This ratio is a leading indicator of future revenue growth and demand health for Charles River's crucial Discovery and Safety Assessment segment, directly impacting backlog and investor confidence. A ratio consistently above 1.0 indicates growing demand. | The DSA net book-to-bill ratio in Q3 2026 and subsequent quarters. In Q2 2026, it was nearly 1.2x, marking the third consecutive quarter above 1x and the highest in nearly four years. | Consistently maintaining or exceeding 1.0x indicates strong demand and expanding backlog (bullish). An acceleration above 1.2x would be a very bullish signal for future revenue. | Charles River Laboratories' Q3 2026 earnings call and investor presentation, typically released in late October - early November 2026. | Industry analyst reports summarizing aggregated CRO book-to-bill trends. | Aggregated CRO Book-to-Bill Ratios: Company Earnings Reports (ICLR, MEDP, IQV, FTRE) |
| Total Company Organic Revenue Growth Acceleration | The return to positive organic revenue growth for the first time since Q3 2023, with expectations for acceleration in the second half of 2026, signals a fundamental improvement in business performance and market demand. | Total company organic revenue growth for Q3 2026 (guided at approximately 1% to 3% year-over-year) and Q4 2026. | Achieving or exceeding the Q3 guidance of 1% to 3% organic growth and further acceleration in Q4 would be a bullish indicator of sustained recovery. | Charles River Laboratories' Q3 2026 earnings call and investor presentation, expected in late October - early November 2026. | Industry reports on overall biopharma R&D spending trends. | |
| Global Biotech Funding Environment | Robust and sustained biotech funding, particularly for small and mid-sized biotechs, directly fuels demand for Charles River's early-stage drug development and safety assessment services. | Trailing 12-month global biotech funding (venture capital and public offerings). It was nearly $100 billion in Q2 2026. Also, monitor biotech IPO activity. | Continued resilience and growth in biotech funding above $100 billion TTM, with increased IPO activity, would be a bullish signal for future demand for CRO services. | PitchBook, SVB Leerink, EvaluatePharma, and other industry analyst reports (quarterly/annually). Management commentary on the funding environment in earnings calls. | Subreddits like r/biotech for biotech funding sentiment and early-stage pipeline activity. | PitchBook: Global Biotech Funding (Venture Capital & Public Offerings) |
| DSA Operating Margin Improvement from NHP Sourcing Costs | Lower non-human primate (NHP) sourcing costs, primarily from the K.F. Cambodia acquisition, are a significant driver for DSA segment operating margin expansion, directly impacting profitability and overall company earnings. | DSA operating margin in Q3 and Q4 2026. Management expects a minimal impact in Q3 and a significant margin contribution in Q4, leading to the highest DSA operating margin in Q4. | A significant year-over-year and sequential improvement in DSA operating margin in Q4 2026, driven by the realization of lower NHP sourcing costs, would be a bullish signal. | Charles River Laboratories' Q3 2026 and Q4 2026 earnings calls and investor presentations. Q3 results are expected in late October - early November 2026. | ||
| Manufacturing Segment Organic Revenue Growth & Operating Margin | The Manufacturing segment's expected improvement to mid-to-high single-digit organic growth and operating margins approaching 40% in the second half of 2026 will be a meaningful contributor to overall company performance and profitability. | Manufacturing segment organic revenue growth and operating margin for Q3 and Q4 2026. | Achieving mid-to-high single-digit organic growth and operating margins approaching 40% in H2 2026 would be a bullish signal, confirming the benefits of divestitures and business rebound. | Charles River Laboratories' Q3 2026 and Q4 2026 earnings calls and investor presentations. Q3 results are expected in late October - early November 2026. |
EPS growth reflects the company's profitability and efficiency. Despite a Q2 decline, management's raised full-year guidance and projected Q3 YoY growth highlig
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Non-GAAP Earnings Per Share Growth | -3.2% | EPS growth reflects the company's profitability and efficiency. Despite a Q2 decline, management's raised full-year guidance and projected Q3 YoY growth highlight improving operational performance and investor focus on earnings trajectory. |
| Total Company Organic Revenue Growth | 0.1% | This is the primary indicator of Charles River's overall business health. Its return to positive organic growth for the first time since Q3 2023 demonstrates a significant turnaround and will be closely watched for sustained acceleration. |
| DSA Organic Revenue Growth | 0.2% | This metric is crucial as DSA is Charles River's largest segment. Its return to positive organic growth, supported by strong bookings and NHP supply, signals a robust recovery in biopharmaceutical demand and is a key driver for future revenue. |
Can Charles River Laboratories sustain and accelerate its organic revenue growth in the DSA and Manufacturing segments in Q3 and Q4 2026, validating the improve
Can Charles River Laboratories sustain and accelerate its organic revenue growth in the DSA and Manufacturing segments in Q3 and Q4 2026, validating the improved biopharmaceutical demand environment and strong book-to-bill?
Will Charles River Laboratories successfully realize the projected operating margin expansion in Q3 and Q4 2026, driven by the full benefits of divestitures and the anticipated significant impact of lower NHP sourcing costs in the DSA segment?
To what extent will Charles River Laboratories' strategic advantages, including its controlled NHP supply and deepening AI integration, translate into market share gains and improved pricing power amidst the competitive CRO landscape over the next quarter?
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Execution on financial targets and Pathway to Purpose strategy:** Management is focused on achieving financial targets, driving shareholder value, and executing their 'Pathway to Purpose' strategy, which includes modernizing the company and industry, strengthening their scientific portfolio, and adopting a client-centric approach. 2. **Portfolio refinement and strategic investments:** Management has completed divestitures to streamline offerings and focus on core competencies in regulated testing solutions. They are also investing organically in scientific capabilities, such as lab sciences and bioanalysis, and utilizing new technologies like AI to modernize their scientific portfolio. 3. **Securing Non-Human Primate (NHP) supply chain:** By acquiring NHP suppliers in Cambodia and Mauritius, Charles River Laboratories has gained control over the NHP supply chain, which is seen as a competitive advantage for regulatory required safety assessment studies, ensuring quality, logistics, and timing of shipments. | Call Takeaway & ToneThe overall takeaway of the call is cautiously optimistic. Charles River Laboratories delivered better-than-expected Q2 2026 financial results, exceeding prior outlooks for revenue and non-GAAP EPS. The company saw a return to organic revenue growth for the first time since Q3 2023, driven by strengthening biopharmaceutical demand, particularly in the DSA segment, and improved booking activity. Management is confident in their 'Pathway to Purpose' strategy, which includes portfolio refinement, strategic investments in scientific capabilities, and leveraging NHP supply chain control as a competitive advantage. The tone was positive regarding the improving demand environment and operational execution, with a clear line of sight for margin improvement in the second half of the year, although management maintained a cautious stance on the immediate material impact of AI and future pricing improvements. | Prior Quarter'S Y/Y Growth By SegmentIn Q1 2026, RMS organic revenue decreased by 5.5%. DSA organic revenue decreased by 1.4%. Manufacturing organic revenue increased by 2.9%. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Impact of AI on preclinical pipeline:** Analysts inquired about the evolving preclinical pipeline due to smarter drug discovery with AI. Management responded that AI is expected to be a tailwind by increasing molecule design productivity, leading to more programs moving into validation and regulated safety assessment. They also noted internal investments in AI tools for efficiency and differentiation, expecting a positive impact over the next few years, though material impact timing is harder to estimate. 2. **Portfolio refinement (divestitures/M&A) and capital allocation:** Analysts asked about the current shape of the business after divestitures and appetite for future deals. Management stated they are comfortable with the current shape, seeing benefits from divestitures in terms of focus and operating margin. They continue to evaluate their portfolio, have a healthy appetite for M&A in clear target areas, and highlighted their strong balance sheet to support future acquisitions. 3. **DSA margin cadence and NHP cost benefits:** Analysts pressed on the timing of the NHP cost benefits from the K.F. acquisition impacting DSA margins. Management clarified that the minimal impact is expected in Q3, with the largest impact and highest DSA operating margins projected for Q4. This is due to the time required for NHP importation, quarantine, acclimation, and placement on studies before the lower direct costs are fully realized. | Revenue SegmentsRMS revenue declined 1.4% organically. DSA revenue increased 0.2% organically. Manufacturing revenue increased 1.3% organically. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketCharles River Laboratories announced a unique collaboration with Eli Lilly's TuneLab drug discovery platform to provide nonclinical or wet lab testing expertise to help build and optimize Eli Lilly's AI and machine learning drug discovery model. The company is utilizing new technologies, including AI, to modernize and strengthen its own scientific portfolio, such as an enhanced digital pathology solution designed to improve study turnaround times and increase pathologists' efficiency. They are investing organically in scientific capabilities, specifically in lab sciences and bioanalysis, with five ongoing lab sciences expansions globally, including a new bioanalytical laboratory capacity at Heriot Watt University's Research Park in Scotland. A collaboration with Arovella Therapeutics was announced to provide next-generation sequencing (NGS) services to accelerate progress towards alternative cancer treatment approaches using cell and gene therapy, leveraging the recent acquisition of PathoQuest. The DSA net book-to-bill rose to nearly 1.2x in the second quarter, marking the third consecutive quarter above 1x and the highest level in nearly four years. The company also reported a return to organic revenue growth of 0.1% for the total company, the first time since the third quarter of 2023. Small and midsized biotech clients are leading the demand strengthening due to an invigorated funding environment, with trailing 12-month funding of nearly $100 billion, just shy of peak pandemic levels. Global biopharmaceutical clients were also significant contributors to improving DSA demand KPIs. Regulatory required safety assessment studies utilizing non-human primates (NHPs) have become a competitive advantage due to a more reliable supply after acquisitions of suppliers in Cambodia and Mauritius. | About CompetitionCharles River Laboratories believes there are abundant opportunities to differentiate itself from the competition with its strong financial profile, refreshed strategic vision, and scientific expertise focused on core regulated testing capabilities. The company views its reliable supply of non-human primates (NHPs), secured through acquisitions in Cambodia and Mauritius, as a competitive advantage for regulatory required safety assessment studies, enabling them to gain market share. In China, the market for early-stage capabilities like chemistry and biology has structurally shifted to lower-cost countries, including China and India. Charles River is prepared to differentiate itself in Western markets with its services, speed, and supply chain against Chinese competition. Global biopharma clients are seen as understanding the difficulty of maintaining the necessary scale and capability for regulated Safety Assessment in-house, preferring partners like Charles River. The company noted a 'nice uptick' in its capture rates, indicating that its go-to-market approach, pricing strategies, and differentiation strategy are working. While pricing for CROs working for Western clients in China is moderating, it remains lower than Western pricing, and pricing for Chinese biotech and pharma is 'still considerably lower'. | About The Broader IndustryThe biopharmaceutical demand environment continued to strengthen in the second quarter, particularly in the Discovery and Safety Assessment (DSA) segment, with overall biopharma demand sustainably improving. Small and midsized biotech clients are driving this trend, supported by an invigorated funding environment that saw nearly $100 billion in trailing 12-month funding, close to peak pandemic levels. Funding activity has been resilient and broad-based, including increased IPO activity and solid venture capital and follow-on funding. Global biopharmaceutical clients have largely completed restructuring and pipeline reprioritization, showing gradually improving demand trends over the last 18 months, with a focus on advancing more molecules into the clinic and seeking approvals. The future of drug discovery and development is expected to integrate traditional in vivo and in vitro solutions with AI and in silico approaches to enhance speed and scientific data. AI is recognized as a 'hot topic' that is expected to drive productivity in molecule design and target identification, leading to more programs entering validation and regulated safety assessment. Conversely, spending from academic and government clients remains constrained by flat NIH budgets and slower grant processing, impacting research models business in North America. The market for early-stage chemistry and biology services has structurally shifted to lower-cost countries like China and India. There is a 'wait-and-see approach' among biotech clients regarding early-stage work in China due to geopolitical uncertainties, with no major shift back to Western providers yet. Industry pricing has remained stable at levels seen over the last few years, with no material improvement or increased discounting, though an uptick is anticipated as capacity utilization improves. New company formation in biotech is growing at only 2%, 'far off from the COVID levels'. | Where Things Are HeadedCharles River Laboratories is raising its financial guidance for the year and expects to drive higher organic growth in the second half of the year, supported by strengthening booking activity. The company's 'pathway to purpose' strategic framework, which includes modernizing the company and industry, strengthening its scientific portfolio, and offering a customized client-centric approach, is key to future success. An enhanced digital pathology solution is expected to cut at least one week from standard pathology timelines. Organic investments in scientific capabilities, particularly lab sciences and bioanalysis, are ongoing to support future growth. The company anticipates becoming an even more essential partner to clients as biopharma demand improves, aiming to gain a greater share of R&D spend. The DSA growth rate is expected to accelerate in the second half of the year, with the full-year DSA outlook raised to low single-digit organic revenue growth, though recovery is expected to be gradual. The Manufacturing segment's organic growth rate is projected to improve to mid- to high single-digit rates in the second half, with its operating margin approaching 40% due to the full benefit of the CDMO divestiture. The company expects at least 500 basis points of margin improvement in the second half of the year, primarily from portfolio actions and lower NHP sourcing costs, with the largest impact in Q4. Non-GAAP earnings per share guidance was increased to a range of $11.15 to $11.45, representing 8% to 11% year-over-year growth. AI is viewed as a 'tailwind' that will drive demand for safety assessment and validation, with positive impact expected over the next few years, though the material ramp-up will take time. Charles River will continue to evaluate its portfolio for refinement, including site consolidations and M&A, with a 'healthy appetite for M&A' in clear target areas, supported by a strong balance sheet. Free cash flow projections were raised to a range of $400 million to $420 million. For Q3, organic revenue growth is expected at 1% to 3% year-over-year, with operating margin projected to improve approximately 200 basis points sequentially, and non-GAAP EPS in the range of $2.90 to $3.00. The company plans to provide a deep dive on NAMs (New Approach Methodologies) development at its upcoming Investor Day, focusing on integrating NAMs into Safety Assessment workflows. | Updates On ThemeCROs: | Broader Themes EmergingAI integration for efficiency and innovation across industries, geopolitical de-risking of supply chains, and modernization of industries through digital solutions. | Bullish-Leaning Quotes (Short)I'm pleased to report that we delivered on our second quarter financial targets, exceeding our prior outlook for the quarter and that we are raising our financial guidance for the year. The DSA net book-to-bill rose to nearly 1.2x in the second quarter, making this the third consecutive quarter that the DSA net book-to-bill has been above 1x and our highest level achieved in nearly 4 years. Our constructive view was also supported by a return to organic revenue growth of 0.1% for the total company, which marks the first time that revenue has improved organically since the third quarter of 2023. We firmly believe these trends position us well to drive higher organic growth during the second half of the year. AI is a hot topic everywhere... we expect more programs to work itself through the safety assessment stage... and we expect that it will actually be a tailwind for us and drive demand. We are in a very healthy state of having animals available. We are really differentiated now because of that nonhuman primate supply. And we see that as a possibility, obviously, to gain market share. | Bearish-Leaning Quotes (Short)While we continue to monitor for changes in the funding environment, whether it be from interest rates and inflation pressures or other macroeconomic factors, funding activity has been resilient and broad-based to date. For the year, we continue to expect a low to mid-single-digit organic revenue decline in the RMS segment, with much of this decline driven by lower volumes for research models in North America. This is largely because spending from academic and government clients has been constrained by flat NIH budgets and slower grant processing. Pricing has not materially improved yet. So, pricing is still stable. It is at the levels that we have seen for the last few years. Not more discounting, not less discounting. Company formation is growing, but only by 2% and far off from the COVID levels. We are now looking to see what their ability of bringing on more regulated work is -- this is still the minority generally focused on companies that are doing their Phase I work in China. | HiringThe expansion of bioanalytical laboratory capacity in Scotland offers an opportunity to partner with Heriot Watt University on the talent pipeline to support future growth in bioanalysis and the region. The company anticipates making 'adjustments in people' as part of doing business. They are 'adding staffing just based on what we expect from demand' and will train them for revenue pickup. A leader from the industry was hired as Chief Scientific Officer to focus on NAMs development. |
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-08-05 | Charles River Laboratories exceeded Q2 2026 expectations, returning to organic revenue growth and reporting strong DSA bookings. Management raised full-year guidance, anticipating significant H2 margin expansion from NHP sourcing and divestitures. The market reacted very positively, with CRL's stock up 14.25% (t+2 days) compared to SPY's 0.25%, indicating strong confidence in the company's outlook and strategic execution. | Earnings Transcript | Positive | +14.25% (vs SPY: +14.00%) |
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| CRL_d18c27a8 | on September 24 | 2026-09-24 | 2026-09-24 | Charles River Laboratories will host an Investor Day to share information about long-term priorities and financial targets. | This event will provide crucial insights into the company's future strategic direction and financial outlook, potentially impacting long-term investor sentiment and valuation. | Ticker | 2026-08-05 | earnings_transcript |
| CRL_76036562 | literally any day now | 2026-09-02 | 2026-09-16 | Resolution of proposed tax legislation changes in Mauritius is expected. | The outcome of this legislation could impact the company's tax rate and earnings per share, with a lower impact potentially providing upside to current guidance. | Ticker | 2026-08-05 | earnings_transcript |
| CRL_bc24e2af | largely benefit the fourth quarter | 2026-10-01 | 2026-12-31 | Lower non-human primate (NHP) sourcing costs from the K.F. Cambodia acquisition are expected to largely benefit the Discovery and Safety Assessment (DSA) operating margin. | This will drive significant margin contribution in the DSA segment, improving profitability and competitive advantage due to more reliable NHP supply. | Ticker | 2026-08-05 | earnings_transcript |
| CRL_938f431a | For the third quarter | 2026-07-01 | 2026-09-30 | Charles River Laboratories expects non-GAAP earnings per share in the range of $2.90 to $3.00 for the third quarter of 2026. | This provides specific financial guidance for the upcoming quarter, indicating strong year-over-year EPS growth, which is a key performance indicator for investors. | Ticker | 2026-08-05 | earnings_transcript |
| CRL_daee1c00 | For the third quarter | 2026-07-01 | 2026-09-30 | Charles River Laboratories expects organic revenue growth of approximately 1% to 3% year-over-year in the third quarter of 2026. | This indicates a continued positive trend in organic revenue growth, driven by improving demand in DSA and a rebound in Biologics Testing, signaling sustained business recovery. | Ticker | 2026-08-05 | earnings_transcript |
